- Home
- GMED vs EXEL Comparison
GMED vs EXEL Comparison
Compare GMED & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMED | EXEL |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.4B |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GMED | EXEL |
|---|---|---|
| Price | $79.01 | $54.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $100.42 | $46.50 |
| AVG Volume (30 Days) | 1.7M | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 422.67 | 57.95 |
| EPS | ★ 0.90 | 0.79 |
| Revenue | ★ $2,938,931,000.00 | $452,477,000.00 |
| Revenue This Year | $11.13 | $13.61 |
| Revenue Next Year | $6.28 | $13.13 |
| P/E Ratio | $92.99 | ★ $68.70 |
| Revenue Growth | ★ 16.65 | N/A |
| 52 Week Low | $51.79 | $33.76 |
| 52 Week High | $101.40 | $55.91 |
Technical Indicators
Market Signals| Indicator | GMED | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 63.78 |
| Support Level | $75.53 | $40.17 |
| Resistance Level | $86.18 | N/A |
| Average True Range (ATR) | 2.81 | 1.53 |
| MACD | 0.55 | 0.05 |
| Stochastic Oscillator | 33.50 | 73.19 |
Price Performance
Historical ComparisonAbout GMED Globus Medical Inc.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.